Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.
Steven Bialick, DO
Advertisement
Articles by Steven Bialick, DO
Presenters at the 3rd Biennial Miami Precision Medicine 2026 Conference shared insights related to pancreatic cancer, sarcomas, and genitourinary diseases.
Microsatellite instability-high status may make patients suitable candidates to receive agents like pembrolizumab, according to Steven Bialick, DO.
Advertisement
Latest Updated Articles
Why Multidisciplinary Teams Matter in Rare CancerApril 27th 2026
Advancing Sarcoma Care Through Precision MedicineApril 25th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma
3
FDA Approves Dato-DXd for Metastatic Triple-Negative Breast Cancer
4
91 Real-World Survival Outcomes by Risk Features in Patients With HR+/HER2− Early Breast Cancer in the United States
5